Isomorphic Labs in Talks for About $5 Billion in Funding
THE SO WHAT
A $5 billion raise for Isomorphic Labs would cement AI-first drug discovery as a capital-intensive, platform-scale bet — closer to a pharma pipeline than a typical software startup. Biotech operators should plan for a world where model access, data partnerships, and wet-lab integration are the real moats, not algorithms alone.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureKorea to Introduce Cornerstone Lockups to Curb Post-IPO Selloffs
Korea tightening cornerstone lockups is a direct response to post-IPO whiplash—issuers are being pushed toward more stable early cap tables. If you’re planning a listing in that market, model longer capital commitment from anchor investors and slower liquidity for insiders.
Startups & VentureMonths-Old Chip Startup Tenspresso in Talks for $500 Million Valuation
A three-month-old AI chip startup like Tenspresso chasing a $500 million valuation shows how capital is still flooding into alternative silicon bets. For buyers, the opportunity is leverage — use this wave to negotiate better terms from incumbents — but be cautious about locking critical workloads to unproven vendors.
Startups & VentureGoldman, Apollo in Talks to Sell SpaceX’s $40 Billion AI Deal
Syndicating a roughly $40 billion chip financing deal into the broader market—just as the political winds shift on AI—turns one company’s infra bet into systemic exposure. If you’re planning large AI capex, expect lenders to scrutinize regulatory and demand risk far more aggressively than they did 12 months ago.
Startups & VentureCrunchbase Data: Less Than 2% Of 2026 Venture Funding Went To Post-Election Red States
With less than 2% of 2026 venture dollars flowing to post-election red states, capital is clustering even harder in purple and blue hubs. Founders in red geographies should plan for more remote-first fundraising and consider entity or HQ arbitrage if local capital dries up.